bristol melanoma drug extends survival in study
bristol-myers squibb co's eagerly anticipated experimental drug ipilimumab extended survival of previously untreated patients with advanced melanoma in a late stage study, the company said.
http://feeds.reuters.com/~r/reuters/healthnews/~3/mdj7rkeak5u/us-bristolmyers-melanoma-idustre72k7ct20110321
25202
21 Mar 2011 23:37:24
reuters
health